Vascular Flow Technologies Partners With Biovic to Develop Avatar Spiral Laminar Flow Graft


November 29, 2017—Vascular Flow Technologies (VFT), a United Kingdom-based developer of spiral laminar flow (SLF) technology, recently announced the successful conclusion of a strategic intellectual property out-licensing agreement with Malaysia-based Biovic Sdn bhd. With this partnership, VFT's SLF technology will be used to enhance Biovic's existing Avatar expanded polytetrafluoroethylene vascular graft. VFT and Biovic will collaborate to bring the Avatar SLF graft to the market by the second quarter of 2018.

VFT advised that it is pursuing collaborative SLF product development across multiple treatment areas including peripheral stents, hybrid stent grafts, and hemodialysis catheters.

According to the company, SLF technology eliminates the turbulent blood flow seen in diseased vessels and standard prosthetic vascular grafts. The technology is designed to replicate the distinctive singular spiral flow pattern of natural blood flow, thereby creating a longer-lasting graft or stent, which can result in a better quality of life for the patient because of reduced vascular complications and improved longevity of the implant.

The company noted that turbulent blood flow at the point where an endovascular implant joins with the blood vessel is a major cause of neointimal hyperplasia that can result in vessel blockage. The spiral flow within the implant is designed to reduce turbulence distally, and in the cases of bypass and arteriovenous access grafts, has shown significant improvements in outcomes.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.